Technical Analysis for 0KBS - Recordati Industria Chimica e Farmaceutica S.p.A.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 49.25 | 1.20% | 0.59 |
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Slingshot Bearish | Bearish Swing Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 20 DMA | Bearish | 1.20% | |
Calm After Storm | Range Contraction | 1.20% | |
Narrow Range Bar | Range Contraction | 1.20% |
Get this analysis on your stocks daily!
Recordati Industria Chimica e Farmaceutica S.p.A. Description
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Classification
Keywords: Medicine Pharmaceuticals Medical Specialties Clinical Medicine Monoclonal Antibodies Rare Diseases Radiation Radiation Therapy Schizophrenia Hematopoietic Stem Cell Transplantation Infectious Causes Of Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 53.19 |
52 Week Low | 37.79 |
Average Volume | 349 |
200-Day Moving Average | 45.62 |
50-Day Moving Average | 50.67 |
20-Day Moving Average | 50.13 |
10-Day Moving Average | 49.37 |
Average True Range | 1.15 |
RSI (14) | 44.13 |
ADX | 32.96 |
+DI | 28.63 |
-DI | 24.37 |
Chandelier Exit (Long, 3 ATRs) | 49.68 |
Chandelier Exit (Short, 3 ATRs) | 52.10 |
Upper Bollinger Bands | 52.50 |
Lower Bollinger Band | 47.76 |
Percent B (%b) | 0.31 |
BandWidth | 9.46 |
MACD Line | -0.46 |
MACD Signal Line | -0.37 |
MACD Histogram | -0.0876 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 49.44 | ||||
Resistance 3 (R3) | 49.42 | 49.33 | 49.41 | ||
Resistance 2 (R2) | 49.33 | 49.28 | 49.34 | 49.40 | |
Resistance 1 (R1) | 49.29 | 49.25 | 49.31 | 49.31 | 49.39 |
Pivot Point | 49.20 | 49.20 | 49.21 | 49.21 | 49.20 |
Support 1 (S1) | 49.16 | 49.15 | 49.18 | 49.18 | 49.10 |
Support 2 (S2) | 49.07 | 49.12 | 49.08 | 49.09 | |
Support 3 (S3) | 49.03 | 49.07 | 49.08 | ||
Support 4 (S4) | 49.05 |